OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Musculoskeletal Disease is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI	137
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment	76
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis	43
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome	41
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis	32
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study	31
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review	30
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients	30
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis	29
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data	29
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)	28
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients	27
Cardio-rheumatology: integrated care and the opportunities for personalized medicine	27
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials	26
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors	26
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study	25
Health disparities in rheumatoid arthritis	23
Calcineurin inhibitors in systemic sclerosis – a systematic literature review	23
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids	23
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry	23
Stromal vascular fraction therapy for knee osteoarthritis: a systematic review	21
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs	21
Future challenges in rheumatology – is telemedicine the solution?	20
Sjögren syndrome: looking forward to the future	19
A glimpse into the future of systemic lupus erythematosus	19

Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues	18
Real-world evidence to assess the effectiveness of platelet-rich plasma in the treatment of knee degenerative pathology: a prospective observational study	18
Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome	17
The association between gout flares and monosodium urate burden assessed using musculoskeletal ultrasound in patients with gout	17
Early knee OA definition–what do we know at this stage? An imaging perspective	17
Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study	17
Advanced imaging techniques in crystal arthritis	16
Effects of acupuncture versus placebo on clinical status and potential specific effects in Fibromyalgia: an umbrella review of 11 meta-analyses	16
Intramuscular methylprednisolone administration in hand osteoarthritis patients: a feasibility study to inform a randomized controlled trial	16
T-score discordance between hip and lumbar spine: risk factors and clinical implications	16
Role of imaging for eligibility and safety of a-NGF clinical trials	16
Gout increases length of stay in patients hospitalized for heart failure exacerbation	15
Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients	15
Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA	15
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care	15
Evaluation of local tissue peri-implant reaction in total knee arthroplasty failure cases	14
Systemic lupus erythematosus is associated with increased risk of Parkinson’s disease	14
Magnetic resonance imaging assessments for knee segmentation and their use in combination with machine/deep learning as predictors of early osteoarthritis diagnosis and prognosis	14
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review	13
The analysis of the pulmonary domain involvement in Sjögren’s disease	13
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers	13
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis	13
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)	13
MRI lesions in SpA: a comparison with noninflammatory back pain using propensity score adjustment method	13
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series	13
A broad look into the future of rheumatoid arthritis	12
Precision medicine in axial spondyloarthritis: current opportunities and future perspectives	12
Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested case–control study	12
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus	12
Precision medicine using molecular-target drugs in psoriatic arthritis	12
SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD	11
A glance into the future of myositis therapy	11
Latest insights in disease-modifying osteoarthritis drugs development	11
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort	11
Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose	11
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy	11
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthr	10
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on ‘Diagnosis, risk stratification, and continuity of care of fragility fractures’ based on a systematic	10
Increased risks of aortic regurgitation and atrial fibrillation in radiographic axial spondyloarthritis patients: a 10-year nationwide cohort study	10
The application of machine learning in early diagnosis of osteoarthritis: a narrative review	10
Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab	10
Muscle health in ankylosing spondylitis: effects of disease duration, inflammation, education level, and spinal mobility on skeletal muscle atrophy	10